

HEPATITIS C TREATMENT AND LINKAGE TO CARE IN PATIENTS WITH MENTAL ILLNESS WHO USE DRUGS: A CORE TEAM NETWORK

Erika Castro¹, Nur Sampaio¹, Aurélie Augsburger¹, Lorenza Oprandi¹

¹Policlinique d'addictologie-Service de Psychiatrie Communautaire-Departement de Psychiatrie - Centre Hospitalier Universitaire Vaudois (CHUV). Lausanne, Switzerland.

erika.castro-bataenjer@chuv.ch

BACKGROUND

The center offers outpatient care and harm reduction services for people with co-occurring drug abuse and mental disorders.

AIM

To discuss hepatitis C treatment and linkage to care strategies in a subset of individuals identified with chronic hepatitis C during 2014.

METHODS

Between 2014 and 2017, we integrated HCV screening, onsite chronic hepatitis C monitoring, fibroscan testing, and DAA prescription to the routine follow-up of patients in collaboration with local healthcare workers and networks. Cross-training of healthcare staff was developed by different clinical paths and interventions.

RESULTS

- Overall, 33 (26.4%) patients were treated with DAA regimens according to drug-drug interactions with ongoing medications and national hepatitis C treatment labels.
- All patients were under opioid substitution treatment, 87.8% (n=29) were treated for at least 1 concomitant mental condition and self-assessment for parallel illegal opioid use was present in 84.8% (n=28) subjects during the span of DAA treatment.
- SVR at end of treatment (EOT) was achieved by 96.9% (n=32) of patients.


CONCLUSIONS

Globally, 102 patient-years of core team follow-up were needed to achieve 97% EOT in this subset of 33 individuals.

Number of HCV treatment per year increased from 3 to 16 (~5 times) with core team network alliances and DAA treatment onsite prescription.

Linkage to care and hepatitis C treatment in patients with dual diagnosis requires interdisciplinary and transversal core teams at both patient and network levels.

START	ALL PATIENTS	Anti-HCV +	HCV RNA +	DAA	SVR
2014	446	223	125	33	32
%	100	50	28	7	7




DAA treatment increased 4 times over 3 years in accordance to onsite HCV skilling and tx prescription as well as national improvement of access to DAAs.



ACKNOWLEDGEMENT

We are grateful to all patients for their contribution to this data as well as to staff colleagues and healthcare partners from the local network.

ONSITE RESSOURCES AND CORE TEAM DOMAINS



BUILDING SKILLS TO LINK PATIENTS TO CARE



In 2017 still an important proportion of patients receiving DAA treatment had liver cirrhosis. Being HCV genotypes 1 and 3 equally represented.

CO-SPONSOR

We thank Gilead Switzerland for co-sponsoring presenting author's attendance to the conference.